Swiss pharmaceutical company Novartis has filed a lawsuit against President Joe Biden's administration over a disagreement regarding the 340B Drug Discount Program. The company claims that the U.S. Health Resources and Services Administration interpreted a federal law wrongly, preventing Novartis from changing payment terms for participating hospitals. This move by Novartis could have significant repercussions on the negotiation process for the company's popular heart drug, Entresto, and its pricing under Medicare. Stay updated on market-moving news with TheFly and check out top-performing stocks on TipRanks.
Novartis Sues Biden Administration Over 340B Drug Discount Program
Swiss pharmaceutical giant Novartis has filed a lawsuit against the Biden administration over a disagreement regarding the 340B Drug Discount Program. The company claims that the U.S. Health Resources and Services Administration (HRSA) interpreted a federal law wrongly, preventing Novartis from changing payment terms for participating hospitals.
The 340B Drug Discount Program is a federal program that was established in 1992 to provide discounted prescription drugs to low-income and uninsured patients. Hospitals that participate in the program are required to pass along the discounts they receive from drug manufacturers to patients.
Novartis argues that the HRSA has misinterpreted the 340B law by requiring drug manufacturers to provide discounts to hospitals regardless of whether the drugs are actually used to treat low-income or uninsured patients. The company says that this interpretation of the law has led to "significant overpayments" to hospitals and that it has been forced to subsidize the program with its own profits.
The lawsuit could have significant repercussions on the negotiation process for Novartis's popular heart drug, Entresto. The drug is currently covered under Medicare Part D, and Novartis is seeking to change the payment terms for Entresto in order to increase its profits. The lawsuit could delay or prevent Novartis from making these changes, which could impact the price of Entresto for Medicare beneficiaries.
Background
The 340B Drug Discount Program was created as part of the Omnibus Budget Reconciliation Act of 1990. The program was originally designed to help hospitals that serve a disproportionate share of low-income and uninsured patients. The program has since been expanded to include a wider range of hospitals, including many that do not serve a disproportionate share of low-income and uninsured patients.
In 2010, the Affordable Care Act made significant changes to the 340B program. The changes included adding new eligibility requirements for hospitals and increasing the discounts that drug manufacturers are required to provide.
Top 5 FAQs
1. What is the 340B Drug Discount Program?
The 340B Drug Discount Program is a federal program that requires drug manufacturers to provide discounts to hospitals that serve a disproportionate share of low-income and uninsured patients. The program is designed to help these hospitals provide affordable prescription drugs to their patients.
2. What is Novartis's lawsuit about?
Novartis is suing the Biden administration over the HRSA's interpretation of the 340B law. Novartis argues that the HRSA is requiring drug manufacturers to provide discounts to hospitals regardless of whether the drugs are actually used to treat low-income or uninsured patients.
3. What could the lawsuit mean for Novartis?
The lawsuit could delay or prevent Novartis from making changes to the payment terms for its popular heart drug, Entresto. This could impact the price of Entresto for Medicare beneficiaries.
4. What could the lawsuit mean for the 340B program?
The lawsuit could have a significant impact on the 340B program. If Novartis is successful in its lawsuit, it could lead to changes in the way that the program is administered. This could make it more difficult for hospitals to participate in the program or could reduce the discounts that hospitals receive from drug manufacturers.
5. What is the future of the 340B program?
The future of the 340B program is uncertain. The program has been the subject of ongoing debate, with some stakeholders arguing that it is too costly and that it does not effectively target low-income and uninsured patients. However, the program remains popular with hospitals and patient advocates, and it is likely to continue to be a source of controversy in the years to come.
After months of anticipation, the Revo Casino and Social House is finally set to open its doors in Conway. While owner Dick Anagnost initially announced a February 1 opening, a new statement from a spokesperson has revealed that the launch date has been moved up to January 29. The highly-anticipated casino is expected to become a major hotspot for entertainment and socializing in the area.
The Indian government recently introduced the Unified Pension Scheme (UPS), which combines features from the National Pension System (NPS) and the old pension scheme. Set to be implemented by April, the UPS aims to bridge key gaps in retirement planning for government employees. This move has the potential to significantly impact the financial future of a significant portion of India's workforce.
Jupiter, the leading decentralized exchange on Solana, has begun its Jupuary airdrop, making over 2 million wallets eligible to claim 700 million JUP tokens. This airdrop, one of the largest in recent times, aims to boost community engagement and onboard users. Despite some initial challenges with high demand, the airdrop has already caused JUP's trading volume to surge by over 100%. Additionally, JUP has caught the attention of institutional investors, with its recent addition to Grayscale's list of potential investment assets for 2024.
The Indian finance ministry has announced the implementation of the Unified Pension Scheme (UPS) for central government employees starting from April 2025. Under this scheme, employees who opt for it will receive a pension equivalent to 50 per cent of their average basic pay drawn in the 12 months before retirement, provided they complete 25 years of service. The scheme aims to provide guaranteed retirement benefits to nearly 2.3 million central government employees, as approved by the Union Cabinet last year.
In a move to boost sales and accommodate excess milk supply, Amul has decided to reduce the prices of its top products, such as Amul Gold, Amul Taaza, and Amul Tea Special, by Re 1 per litre across India. This price cut is expected to drive demand for larger pack sizes while maintaining Amul's competitive edge in the dairy industry. However, no changes have been made to the prices of other products and packages.
With the constant stream of information on social media, Twitter stands out as a valuable source for breaking news, alerts, and tips for making trading decisions. However, with millions of feeds constantly updating, it can be overwhelming to find useful posts. That's why some money managers use social media dashboard apps to filter their results. For individual investors looking to stay on top of the latest financial news, consider following these 10 feeds, including well-known outlets like CNBC and The Wall Street Journal, as well as lesser-known sources like Stocktwits and @BreakoutStocks.
In recent months, Archer Aviation Inc (ACHR) has seen a significant increase in stock price, gaining over 116% in the past six months and 223% in the last three months. Despite this volatility, the company boasts a gross margin of 116.89% and a strong profit margin, making it an attractive investment for many. However, with market capitalization at $4.21 billion and a Price-to-Book Ratio of 8.98, investors may want to approach with caution. Additionally, insider trades by top executives, including a recent sale of 191,513 shares by Director Michael Spellacy, may also impact the stock's performance. With industry experts like JP Morgan placing a Neutral rating on the company, investors should closely monitor Archer Aviation Inc (ACHR) stock for potential fluctuations.
Despite entering a new year, MicroStrategy, led by CEO Michael Saylor, continues its acquisition strategy for Bitcoin as it buys another $101 million worth of the cryptocurrency. This brings their total holdings to an impressive 447,470 BTC. The company recently sold off shares to finance the purchase, but still has plans to acquire more BTC in the future. The firm's recent purchase is part of their 21/21 plan, which includes equity and fixed-income securities capital raise to fund further BTC purchases.
Inspired by a private bus on the Kasaragod-Bantadukka route, KSRTC is considering converting its old superfast buses to air-conditioned ones. This initiative comes as a response to the growing demand for AC premium buses. Technical experts have been appointed to study the feasibility, with the aim to reduce the cost of conversion to ₹4 lakh per bus. The private company's innovative mechanism, which uses a dynamo to generate electricity, is expected to improve fuel efficiency.
Volvo's highly anticipated EX30 electric SUV, originally promised at an affordable price, will now have a higher price tag due to production delays and potential tariffs. The car's compact design and competitive pricing made it a success in Europe, and Volvo is hoping for a similar reception in the US market. Despite the price increase, the EX30 is still set to feature a powerful 422 horsepower engine, making it a strong contender in the EV market.